Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties

Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.

[1]  A. Teschemacher,et al.  Using Light for Therapy of Glioblastoma Multiforme (GBM) , 2020, Brain sciences.

[2]  S. Ogura,et al.  Photoirradiation after aminolevulinic acid treatment suppresses cancer cell proliferation through the HO-1/p21 pathway. , 2019, Photodiagnosis and photodynamic therapy.

[3]  Serge Mordon,et al.  Devices based on light emitting fabrics dedicated to PDT preclinical studies , 2019, World Congress of the International Photodynamic Association.

[4]  S. Mordon,et al.  Photodynamic therapy for skin cancer: How to enhance drug penetration? , 2019, Journal of photochemistry and photobiology. B, Biology.

[5]  G. Emri,et al.  Immunological effects of photodynamic therapy in the treatment of actinic keratosis and squamous cell carcinoma. , 2018, Photodiagnosis and photodynamic therapy.

[6]  C. Jorcyk,et al.  IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis , 2018, Cancer management and research.

[7]  A. Yoshimura,et al.  Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells , 2018, BMC Cancer.

[8]  Simon A. Jones,et al.  Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer , 2018, Nature Reviews Immunology.

[9]  N. Said,et al.  Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities , 2018, Cancer medicine.

[10]  J. Jagdeo,et al.  An In Vitro Approach to Photodynamic Therapy , 2018, Journal of visualized experiments : JoVE.

[11]  G. Ricci,et al.  Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives , 2018, Theranostics.

[12]  Tetiana Korzun,et al.  Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[13]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[14]  Ying Yue,et al.  Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection , 2018, Medicine.

[15]  H. Kajiyama,et al.  Novel potential photodynamic therapy strategy using 5-Aminolevulinic acid for ovarian clear-cell carcinoma. , 2018, Photodiagnosis and photodynamic therapy.

[16]  J. Golding,et al.  Photodynamic therapy and diagnosis: Principles and comparative aspects. , 2017, Veterinary journal.

[17]  S. Mordon,et al.  Photodynamic therapy for actinic keratosis: Is the European consensus protocol for daylight PDT superior to conventional protocol for Aktilite CL 128 PDT? , 2017, Journal of photochemistry and photobiology. B, Biology.

[18]  Chwee Teck Lim,et al.  Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges. , 2017, Trends in biotechnology.

[19]  H. Mizunuma,et al.  Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences. , 2017, Oncology letters.

[20]  P. Lissoni.  Therapy implications of the role of interleukin-2 in cancer , 2017, Expert review of clinical immunology.

[21]  中村 幸司.  Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells , 2017 .

[22]  Joshua M. Weiss,et al.  Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. , 2016, Cancer cell.

[23]  D. Chi,et al.  Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. , 2016, Gynecologic oncology.

[24]  C. Isidoro,et al.  Resveratrol inhibits IL‐6‐induced ovarian cancer cell migration through epigenetic up‐regulation of autophagy , 2016, Molecular carcinogenesis.

[25]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[26]  E. Lengyel,et al.  Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells , 2016, Molecular Cancer Research.

[27]  T. Joh,et al.  Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin) , 2016, Oncotarget.

[28]  S. Mordon,et al.  Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study. , 2016, Photodiagnosis and photodynamic therapy.

[29]  L. Zitvogel,et al.  Natural and therapy-induced immunosurveillance in breast cancer , 2015, Nature Medicine.

[30]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[31]  Dong-hong Li,et al.  Apoptosis of HeLa cells induced by a new targeting photosensitizer-based PDT via a mitochondrial pathway and ER stress , 2015, OncoTargets and therapy.

[32]  S. Mordon,et al.  [FRα: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?]. , 2014, Bulletin du cancer.

[33]  L. Zitvogel,et al.  Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer , 2014, The Journal of Immunology.

[34]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[35]  Yvonne Bordon.  Immunometabolism: IL-6, the resistance fighter , 2014, Nature Reviews Immunology.

[36]  M. Oehler,et al.  New perspectives in ovarian cancer treatment. , 2014, Maturitas.

[37]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[38]  D. O'Shannessy,et al.  Expression of Folate Receptor-&agr; (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[39]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[40]  E. Panzarini,et al.  Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer? , 2012, BioMed research international.

[41]  R. Bast,et al.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. , 2012, Endocrinology.

[42]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[45]  A. Tomassetti,et al.  Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression , 2000, Oncogene.

[46]  C. Frochot,et al.  Folic acid conjugates with photosensitizers for cancer targeting in photodynamic therapy: Synthesis and photophysical properties. , 2017, Bioorganic & medicinal chemistry.

[47]  T. Niki,et al.  Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. , 2015, Journal of the National Cancer Institute.